Florida Drug Import Program Costs $82 Million Zero Drugs

State contractors face no new costs, but the program remains inactive despite years of effort to secure Canadian medication.

Updated on Oct. 28, 2026 in Healthcare

Isometric editorial illustration of a generic, empty concrete warehouse building under bright sun, representing an inactive government drug import program. — Florida has spent over $81.9 million on a prescription drug import program that has yet to import any medications. AI Illustration. Upload story photo >

Live Poll

Should states pursue government-run programs to import prescription drugs to lower costs for the public?

Florida has paid over $81.9 million to LifeScience Logistics for a prescription drug import program that has yet to import any medications. The program, designed to lower costs for state-run initiatives, remains inactive despite FDA approval in 2024.

Why it matters

The program faced significant implementation hurdles due to pharmaceutical manufacturer resistance, leaving state-funded infrastructure in Lakeland underutilized. Operators should note the complexity of international pharmaceutical supply chains when managing state-level compliance and procurement.

Florida paid $81,946,746.74 to LifeScience Logistics, an increase from the initial $38.8 million contract value set in 2020. The current expenditure averages approximately $1.2 million per month since 2021 with no drug imports recorded.

The players

LifeScience Logistics

A Dallas-based third-party logistics firm specializing in healthcare warehousing and supply chain management.

Agency for Health Care Administration

The Florida state agency responsible for overseeing the drug importation program and managing the state contract.

FDA

The federal agency tasked with regulating prescription drug imports and public health safety.

The details

The program relies on a warehouse facility in Lakeland, Florida, operated by the Dallas-based firm LifeScience Logistics. Florida negotiated the contract after receiving no bids from other companies to manage the logistics of importing Canadian prescription drugs. While the state government initially planned for a streamlined importation process, implementation stalled as manufacturers resisted the supply chain change.

Dec. 30, 2020: Florida signed the initial contract with LifeScience Logistics.
Dec. 2022: The state renewed the contract for three years.
2024: The FDA granted approval for the state import program.
April through June 2026: Official state report confirms zero imports occurred.
July 2026: State payments to the logistics firm ceased.

Market Landscape

The program represents a departure from the anticipated rollout of the Florida Canadian Prescription Drug Importation Program, which aimed to establish a new supply chain model. This outcome highlights the regulatory and industry challenges inherent in executing state-led pharmaceutical importation strategies.

Operators in the pharmaceutical and logistics space should monitor how the state manages the Lakeland warehouse asset moving forward. Compliance hurdles and manufacturer resistance remain key factors that can stall even federally-approved procurement strategies.

The takeaway

This case underscores the difficulty of implementing international drug sourcing due to manufacturer-level market resistance. Owners should prioritize tracking legislative procurement reporting to identify similar supply chain bottlenecks in their own sectors.